GlassScriptPhysician profile
Barbara Nguyen
NPI 1821570383
$11,199.21
in general payments reported to CMS, 2019-2025
26 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,971 · 2022: $2,012 · 2023: $2,650 · 2024: $3,211 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,904 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,904.35 |
| Education | $311.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,909.68 | 2021-2025 | |
| Janssen Biotech, INC. | $1,966.59 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,116.59 | 2021-2025 | Cimzia, Nayzilam, Bimzelx |
| Mallinckrodt Hospital Products INC. | $953.76 | 2021-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $854.43 | 2021-2024 | Saphnelo |
| Pfizer INC. | $571.88 | 2021-2024 | |
| Glaxosmithkline, LLC. | $492.03 | 2021-2024 | Benlysta |
| Amgen INC. | $433.98 | 2023-2025 | Evenity, Tavneos |
| Horizon Therapeutics Plc | $396.61 | 2021-2023 | |
| Lilly USA, LLC | $297.76 | 2021-2024 | Kisunla, Taltz |
| Neurocrine Biosciences, INC. | $128.00 | 2024 | Ingrezza |
| Sk Life Science, INC. | $125.00 | 2025 | Xcopri |
| Aurinia Pharma U.S., INC. | $122.88 | 2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $122.88 | 2024 | Strensiq |
| Novo Nordisk INC | $118.75 | 2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $117.32 | 2023-2024 | Hadlima, Renflexis |
| Eisai INC. | $115.53 | 2024 | |
| Novartis Pharmaceuticals Corporation | $92.00 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $70.99 | 2022-2023 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $43.56 | 2024 | Idacio |
| Fidia Pharma USA INC. | $37.17 | 2021-2024 | Hyalgan, Hymovis, Triluron |
| Sandoz INC. | $26.00 | 2023 | Hyrimoz |
| Teva Pharmaceuticals USA, INC. | $25.07 | 2024 | Truxima |
| Celltrion USA INC. | $24.53 | 2023 | Yuflyma |
| Sobi, INC | $19.46 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.